Eric Stefan
Overview
Explore the profile of Eric Stefan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sauve V, Stefan E, Croteau N, Goiran T, Fakih R, Bansal N, et al.
Nat Commun
. 2024 Sep;
15(1):7707.
PMID: 39300082
Mutations in parkin and PINK1 cause early-onset Parkinson's disease (EOPD). The ubiquitin ligase parkin is recruited to damaged mitochondria and activated by PINK1, a kinase that phosphorylates ubiquitin and the...
2.
Meibom D, Wasnaire P, Beyer K, Broehl A, Cancho-Grande Y, Elowe N, et al.
J Med Chem
. 2024 Feb;
67(4):2907-2940.
PMID: 38348661
The matrix metalloprotease ADAMTS7 has been identified by multiple genome-wide association studies as being involved in the development of coronary artery disease. Subsequent research revealed the proteolytic function of the...
3.
Shlevkov E, Murugan P, Montagna D, Stefan E, Hadzipasic A, Harvey J, et al.
iScience
. 2022 Jan;
25(1):103650.
PMID: 35024585
Pharmacological activation of the E3 ligase Parkin represents a rational therapeutic intervention for the treatment of Parkinson's disease. Here we identify several compounds that enhance the activity of wildtype Parkin...
4.
Corsello S, Nagari R, Spangler R, Rossen J, Kocak M, Bryan J, et al.
Nat Cancer
. 2020 Jul;
1(2):235-248.
PMID: 32613204
Anti-cancer uses of non-oncology drugs have occasionally been found, but such discoveries have been serendipitous. We sought to create a public resource containing the growth inhibitory activity of 4,518 drugs...
5.
Struntz N, Chen A, Deutzmann A, Wilson R, Stefan E, Evans H, et al.
Cell Chem Biol
. 2019 Mar;
26(5):711-723.e14.
PMID: 30880155
The transcription factor Max is a basic-helix-loop-helix leucine zipper (bHLHLZ) protein that forms homodimers or interacts with other bHLHLZ proteins, including Myc and Mxd proteins. Among this dynamic network of...
6.
Chang C, Stefan E, Taylor R
Chemistry
. 2015 Jun;
21(30):10681-6.
PMID: 26101039
Lyngbyaloside C, a classic macrolide, isolated from Lyngbya bouilloni, has shown moderate anticancer activity against several cancer cell lines. Here, we report the first total synthesis and stereochemical configuration reassignment...
7.
Stefan E, Nalin A, Taylor R
Tetrahedron
. 2013 Sep;
69(36):7706-7712.
PMID: 24058215
Ether transfer methodology is capable of stereoselectively generating 1,3-diol mono- and diethers in good yield. Surprisingly, allylic and benzylic substrates provide none of the desired products when exposed to previously...
8.
Stefan E, Taylor R
Org Lett
. 2012 Jun;
14(13):3490-3.
PMID: 22716968
A stereoselective synthesis of the C9-C19 fragment of lyngbyaloside B and C highlighted, by an extension of our ether transfer methodology, enables the formation of tertiary ethers. 2-Naphthylmethyl ethers have...
9.
Haddach M, Pierre F, Regan C, Borsan C, Michaux J, Stefan E, et al.
Bioorg Med Chem Lett
. 2011 Dec;
22(1):45-8.
PMID: 22169261
Protein kinase CK2 is a potential drug target for many diseases including cancer and inflammation disorders. The crystal structure of clinical candidate CX-4945 1 with CK2 revealed an indirect interaction...
10.
Pierre F, Stefan E, Nedellec A, Chevrel M, Regan C, Siddiqui-Jain A, et al.
Bioorg Med Chem Lett
. 2011 Oct;
21(22):6687-92.
PMID: 21982499
A novel class of pan-Pim kinase inhibitors was designed by modifying the CK2 inhibitor CX-4945. Introduction of a triazole or secondary amide functionality on the C-7 position and 2'-halogenoanilines on...